The novel biguanide derivative 4C synergizes with talazoparib by inducing ferroptosis via the SREBP1/FASN/ SLC7A11/GPX4 axis in bladder cancer
Abstract
Bladder cancer (BC) remains a clinically challenging urothelial malignancy, largely because a substantial proportion of patients have no effective treatment options. Epidemiological studies have shown that metformin can improve the survival rate of cancer patients. However, its clinical application is limited by the requirement of high concentrations to exert antitumor effects. To overcome this limitation, we modified and optimized the biguanide structure using the intermediate derivatization methods and obtained a novel biguanide derivative 4C. Our study revealed that 4C suppressed the expression of sterol regulatory element-binding protein 1 (SREBP1), thereby inhibiting the transcription of fatty acid synthase (FASN) and downregulating its protein expression. Concurrently, 4C inhibited the expression of ferroptosis-related regulatory proteins NRF2, SLC7A11, and GPX4, induced ferroptosis and effectively suppressed the proliferation and migration of BC cells. Notably, this inhibitory effect was markedly attenuated by the ferroptosis-specific inhibitor ferrostatin-1. Furthermore, we found that inducing ferroptosis was an effective approach to sensitize BRCA1/2 wild-type BC cells to poly (ADP-ribose) polymerase (PARP) inhibitors. Accordingly, 4C enhanced the sensitivity of BC cells to the PARP inhibitor talazoparib by reducing glutathione (GSH) levels, promoting reactive oxygen species (ROS) accumulation, and increasing malondialdehyde (MDA) levels. However, in the presence of ferrostatin-1, the sensitizing effect of 4C on talazoparib was reversed. In conclusion, this study demonstrated that the combination of 4C and talazoparib induces ferroptosis via the SREBP1/FASN axis, providing a promising novel combination therapeutic strategy for the treatment of BC.
Related
- PRMT1 facilitates the renal ischemia-reperfusion injury by inducing the ferroptosis via mediating the arginine methylation of ACSL4
- Iron overload disrupts bone homeostasis via dual pathways: inducing ferroptosis of preosteoblastic cells and shaping a proinflammatory immune milieu
- Minimal indel-inducing and window-adjustable base editing using inactive Cas12b effectors
- Oleoyl-L-carnitine regulates PPM1B through BIRC6, inducing tumor concomitant cardiac fibrosis
- Structurally diverse triterpenoid alkaloids from Buxus myrica with cytotoxic and apoptosis-inducing activities.
BibTeX
@article{yao2026novel,
title = {{The novel biguanide derivative 4C synergizes with talazoparib by inducing ferroptosis via the SREBP1/FASN/ SLC7A11/GPX4 axis in bladder cancer}},
author = {Jia Yao and Weifan Wang and Duo Li and Cangcang Xu and Xin Yang and Di Xiao and Xiaoping Yang},
journal = {Cell Death Discovery},
year = {2026},
month = jul,
doi = {10.1038/s41420-026-03270-0},
url = {https://doi.org/10.1038/s41420-026-03270-0},
note = {CC BY},
}
RIS
TY - JOUR
TI - The novel biguanide derivative 4C synergizes with talazoparib by inducing ferroptosis via the SREBP1/FASN/ SLC7A11/GPX4 axis in bladder cancer
AU - Jia Yao
AU - Weifan Wang
AU - Duo Li
AU - Cangcang Xu
AU - Xin Yang
AU - Di Xiao
AU - Xiaoping Yang
PY - 2026
DA - 2026/07/01
JO - Cell Death Discovery
DO - 10.1038/s41420-026-03270-0
UR - https://doi.org/10.1038/s41420-026-03270-0
AB - Bladder cancer (BC) remains a clinically challenging urothelial malignancy, largely because a substantial proportion of patients have no effective treatment options. Epidemiological studies have shown that metformin can improve the survival rate of cancer patients. However, its clinical application is limited by the requirement of high concentrations to exert antitumor effects. To overcome this limitation, we modified and optimized the biguanide structure using the intermediate derivatization methods and obtained a novel biguanide derivative 4C. Our study revealed that 4C suppressed the expression of sterol regulatory element-binding protein 1 (SREBP1), thereby inhibiting the transcription of fatty acid synthase (FASN) and downregulating its protein expression. Concurrently, 4C inhibited the expression of ferroptosis-related regulatory proteins NRF2, SLC7A11, and GPX4, induced ferroptosis and effectively suppressed the proliferation and migration of BC cells. Notably, this inhibitory effect was markedly attenuated by the ferroptosis-specific inhibitor ferrostatin-1. Furthermore, we found that inducing ferroptosis was an effective approach to sensitize BRCA1/2 wild-type BC cells to poly (ADP-ribose) polymerase (PARP) inhibitors. Accordingly, 4C enhanced the sensitivity of BC cells to the PARP inhibitor talazoparib by reducing glutathione (GSH) levels, promoting reactive oxygen species (ROS) accumulation, and increasing malondialdehyde (MDA) levels. However, in the presence of ferrostatin-1, the sensitizing effect of 4C on talazoparib was reversed. In conclusion, this study demonstrated that the combination of 4C and talazoparib induces ferroptosis via the SREBP1/FASN axis, providing a promising novel combination therapeutic strategy for the treatment of BC.
SN - 2058-7716
ER -